The use of (auto)antibodies as markers is one of the most promising prognostic and diagnostic approaches to classify disease and requires minimal invasive intervention. (Auto)antibodies are excellent biomarkers because they are robust, naturally amplified by the immune system, immunologically memorized and readily detectable.

The TRON Biomarker Development Center (BDC)’s Serodiscovery Core Facility provides in-house research groups and interested external groups with state-of-the-art technologies for identifying disease-related (auto)antibody signatures from a broad range of body fluids.

Application of our highly innovative technology platforms ranges from various high density peptide microarray formats for high throughput biomarker discovery to traditional ELISA technologies for subsequent biomarker validation. Our platforms have been specially designed for the diagnosis of cancer, autoimmune diseases, infection diseases, and allergies.


A peptide microarray consists of thousands of different peptides (each up to 15 amino acids in length) immobilized on a planar glass substrate. Peptide microarrays comprise three identical subarrays of approximately 7000 different peptides each. We utilize high quality peptide microarrays comprising proprietary control peptides and employ robust and highly sophisticated in-house algorithms for data handling and analysis.

In addition to our technical expertise in serologic biomarker discovery, we help project partners plan research studies, assess feasibility, and analyze data. TRON’s Serodiscovery platform covers all phases of serological biomarker discovery, including design of peptide arrays, screening of biological samples and corresponding data analysis and interpretation.